Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: A systematic review and meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 3, 2011, Pages 345-353

  Tzellos, T G ^a   Sardeli, C ^a   Lallas, A ^b   Papazisis, G ^a   Chourdakis, M ^a   Kouvelas, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hospital for Skin and Venereal Diseases   (Greece)

Author keywords

catechins; condylomata acuminata; genital warts; green tea; polyphenon E

Indexed keywords

CATECHIN; IMIQUIMOD; POLYPHENON E;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BURNING SENSATION; CONDYLOMA ACUMINATUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOLLOW UP; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC REVIEW; TEA; TOPICAL TREATMENT; WART VIRUS;

CATECHIN; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; MALE; PRURITUS; RECURRENCE; SKIN DISEASES, VIRAL; TEA; TREATMENT OUTCOME;

EID: 79751487821     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03796.x     Document Type: Article

References (27)

1. Leung CY,. Genital warts. In, Sa' Cabral P, Leite L, Pinto J, eds. Handbook of Dermatology and Venereology. Social Hygiene Handbook, 2nd edn. Department of Dermatology, Hospital Pulido Valente, Lisbon, 2003: 2.
2. Koutsky L,. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8. (Pubitemid 127695953)
3. Von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76: 162-168. (Pubitemid 30435195)
4. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007; 196: 1447-1454. (Pubitemid 351411979)
5. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-819. (Pubitemid 46333946)
6. Power Y, Dessenne C, Genital Warts. Eurotech Data 60, Grand Rue, 1600, Luxembourg. Dossier No. E18.02, 2002.
7. Birley HD, Kupek E, Byrne M, et al. Clinical features and outcome of first presentation anogenital warts in men and women. J Eur Acad Dermatol Venereol 1994; 3: 198-205. (Pubitemid 24135699)
8. O'Mahony C,. Genital warts: current and future management options. Am J Clin Dermatol 2005; 6: 239-243. (Pubitemid 41159410)
9. Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79: 270-275. (Pubitemid 37026341)
10. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR,. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008; 35: 346-351. (Pubitemid 351440773)
11. American Medical Association. External Genital Warts: Diagnosis and Treatment. AMA, Chicago, IL, 1997.
12. Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. Clin Infect Dis 1999; 28: 37-56.
13. Micali G, Dall'Oglio F, Nasca MR, Tedeschi A,. Management of cutaneous warts: an evidence-based approach. Am J Clin Dermatol 2004; 5: 311-317. (Pubitemid 39655094)
14. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, October 2006-September 2007. MMWR 2006; 55: Q1-Q4.
15. ™ Ointment, 15%, NDA 021902. U.S. Food and Drug Administration, Washington, DC, 2006. URL (last accessed: 3 January 2010).
16. Ahn WS, Huh SW, Bae SM, et al. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G1 arrest, and regulation of gene expression. DNA Cell Biol 2003; 22: 217-224. (Pubitemid 36578095)
17. Shimizu M, Weinstein IB,. Modulation of signal transduction by tea catechins and related phytochemicals. Mutation Res 2005; 591: 147-160. (Pubitemid 41654845)
18. Tomita I, Sano M, Watanabe J, et al. Tea and its components as powerful antioxidants. In, Cutler RG, Packer L, Bertram J, Mori A, eds. Oxidative Stress and Aging, 1st edn. Birkhauser Verlag, Basel, 1995: 355-365.
19. Tatti S, Stockfleth E, Beutner KR, et al. Polyphenon E(R): a new treatment for external anogenital warts. Br J Dermatol 2010; 162: 176-184.
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
21. Langley PC,. A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J Med Econ 2010; 13: 1-7.
22. Gross G, Meyer KG, Pres H, et al. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 2007; 21: 1404-1412. (Pubitemid 350020150)
23. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158: 1329-1338. (Pubitemid 351692865)
24. Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111: 1371-1379.
25. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-239. (Pubitemid 28100838)
26. Insinga RP, Dasbach EJ, Myers ER,. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36: 1397-1403. (Pubitemid 36702873)
27. El-Attar SM, Evans DV,. Anal warts, sexually transmitted diseases, and anorectal conditions associated with human immunodeficiency virus. Prim Care 1999; 26: 81-100. (Pubitemid 29117673)